Genetic Testing & Biomarkers | 2025 Mid-Year Update | Todd Morgan, MD + Mark Moyad, MD Q&A #PCRI @ThePCRI
Genetic Testing & Biomarkers | 2025 Mid-Year Update | Todd Morgan, MD + Mark Moyad, MD Q&A #PCRI  @ThePCRI
Uploaded May 2025 | Updated September 2026, 2 weeks ago
Learn more about Dr. Todd Morgan here:
https://medschool.umich.edu/profile/3567/todd-morgan

4:03 3 Important questions
12:56 Diagnostic testing in prostate cancer
18:29 Who should undergo germline testing?
26:26 Highlights of the 3 gene expression classifier tests
32:35 Clinical trials
37:45 How do I use GEC tests?
41:34 Atera MMAI risk groups
43:43 Predictive signal for hormone therapy
45:09 AI take-home message
53:46 Overall take-home message
55:12 Dr. Moyad & Dr. Morgan Q&A

To learn more about prostate cancer, visit pcri.org
Don't know your stage? Take the quiz: visit prostatecancerstaging.org

Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: pcri.org/join

Donate to PCRI: pcri.org/donate

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) not-for-profit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive better-individualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 95-4617875 and qualifies for maximum charitable gift deductions by individual donors.
Genetic Testing & Biomarkers | 2025 Mid-Year Update | Todd Morgan, MD + Mark Moyad, MD Q&A #PCRIMRI & Active Surveillance for Gleason 6 (3+3) #MarkScholzMD #pcriHot Flashes From Hormone Therapy #ProstateCancer | #MarkScholzMD #AlexScholz #PCRIMRI Surveillance & Gleason 6 (3+3)Optimal Duration of Hormone Therapy For #ProstateCancer | #MarkScholzMD #AlexScholz #PCRIAnswering Your #ProstateCancer Active Surveillance Questions | #MarkScholzMD #AlexScholz #PCRIProstate MRIs & Random Needle Biopsies #PCRIIncontinence After #Prostate Surgery | #MarkScholzMD #PCRI #ProstateCancerChemo, Hormone Therapy, and Radiation For Advanced Metastatic #ProstateCancer #MarkScholzMD #PCRIHow to Read PSMA Scans | #MarkScholzMD #AlexScholz #PCRI #ProstateCancerIDC-P Intraductal Carcinoma of the Prostate | Jonathan Epstein, MD & Mark Moyad, MD, MPH | #PCRIThe Power Of Exercise For Prostate Cancer | Robert Newton, PHD & Q+A with Mark Moyad, MD #PCRI
Prostate Cancer Research Institute |

Genetic Testing & Biomarkers | 2025 Mid-Year Update | Todd Morgan, MD + Mark Moyad, MD Q&A #PCRI

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER